This inventor holds 56 USPTO granted patents and 35 published patent applications and 9 EPO patents, primarily in Cancer Prognosis (CPC class C12Q). Top assignees: Biotheranostics, Inc., Ortho-Mcneil Pharmaceutical Corp., University of California. Active years: 1995-2026.
Inventors with similar research interests:
Location History:
- Tarzana, CA (US) (1995 - 2015)
- San Diego, CA (US) (2002 - 2017)
- Camino del Prado, CA (US) (2016 - 2018)
- Redwood City, CA (US) (2018 - 2020)
- Encinitas, CA (US) (1995 - 2022)
- Carlsbad, CA (US) (2011 - 2023)
Company Filing History:
15 out of 17Â 
11 out of 363Â 
10 out of 15,964Â 
Years Active: 1995-2026
Areas of Expertise:
Title: The Innovative Contributions of Mark G Erlander in Cancer Research
Introduction: Mark G Erlander is a prominent inventor based in Encinitas, California, known for his significant contributions to the field of cancer research. With an impressive portfolio of 53 patents, his work primarily revolves around the diagnosis and treatment of neuroendocrine tumors, showcasing his commitment to advancing medical science.
Latest Patents: One of Erlander's latest patents focuses on neuroendocrine tumors, presenting methods for utilizing gene expression measurements to classify or identify neuroendocrine cancer. This innovation plays a critical role in clinical settings, especially with formalin-fixed, paraffin-embedded (FFPE) samples. Another notable patent addresses the identification of tumors and tissues, again leveraging gene expression measurement techniques to enhance tumor classification from clinical samples.
Career Highlights: Throughout his career, Mark G Erlander has worked with leading companies in the pharmaceutical and biotechnology sectors. Notably, he has been affiliated with Biotheranostics, Inc. and Ortho-McNeil Pharmaceutical Corporation. His expertise has impacted the development of innovative diagnostic tools and therapeutic methods.
Collaborations: Erlander has benefited from collaborations with esteemed colleagues such as Allan J. Tobin and Daniel L. Kaufman. These partnerships have played a crucial role in advancing research and fostering innovation in cancer diagnostics.
Conclusion: Mark G Erlander's dedication to innovation in cancer research has led to numerous patents that enhance our understanding and treatment of neuroendocrine tumors. His contributions not only underscore his role as a leading inventor in the field but also highlight the importance of collaboration in driving scientific progress.